RT Journal Article
T1 Features of Mild-to-Moderate COVID-19 Patients With Dysphonia.
A1 Lechien, Jerome R
A1 Chiesa-Estomba, Carlos M
A1 Cabaraux, Pierre
A1 Mat, Quentin
A1 Huet, Kathy
A1 Harmegnies, Bernard
A1 Horoi, Mihaela
A1 Le Bon, Serge Daniel
A1 Rodriguez, Alexandra
A1 Dequanter, Didier
A1 Hans, Stéphane
A1 Crevier-Buchman, Lise
A1 Hochet, Baptiste
A1 Distinguin, Lea
A1 Chekkoury-Idrissi, Younes
A1 Circiu, Marta
A1 El Afia, Fahd
A1 Barillari, Maria Rosaria
A1 Cammaroto, Giovanni
A1 Fakhry, Nicolas
A1 Michel, Justin
A1 Radulesco, Thomas
A1 Martiny, Delphine
A1 Lavigne, Philippe
A1 Jouffe, Lionel
A1 Descamps, Géraldine
A1 Journe, Fabrice
A1 Trecca, Eleonora M C
A1 Hsieh, Julien
A1 Delgado, Irene Lopez
A1 Calvo-Henriquez, Christian
A1 Vergez, Sebastien
A1 Khalife, Mohamad
A1 Molteni, Gabriele
A1 Mannelli, Giuditta
A1 Cantarella, Giovanna
A1 Tucciarone, Manuel
A1 Souchay, Christel
A1 Leich, Pierre
A1 Ayad, Tareck
A1 Saussez, Sven
K1 Clinical
K1 Coronavirus
K1 Covid-19
K1 Dysphonia
K1 ENT
K1 Findings
K1 Symptoms
K1 Voice
AB To explore the prevalence of dysphonia in European patients with mild-to-moderate COVID-19 and the clinical features of dysphonic patients. The clinical and epidemiological data of 702 patients with mild-to-moderate COVID-19 were collected from 19 European Hospitals. The following data were extracted: age, sex, ethnicity, tobacco consumption, comorbidities, general, and otolaryngological symptoms. Dysphonia and otolaryngological symptoms were self-assessed through a 4-point scale. The prevalence of dysphonia, as part of the COVID-19 symptoms, was assessed. The outcomes were compared between dysphonic and nondysphonic patients. The association between dysphonia severity and outcomes was studied through Bayesian analysis. A total of 188 patients were dysphonic, accounting for 26.8% of cases. Females developed more frequently dysphonia than males (P = 0.022). The proportion of smokers was significantly higher in the dysphonic group (P = 0.042). The prevalence of the following symptoms was higher in dysphonic patients compared with nondysphonic patients: cough, chest pain, sticky sputum, arthralgia, diarrhea, headache, fatigue, nausea, and vomiting. The severity of dyspnea, dysphagia, ear pain, face pain, throat pain, and nasal obstruction was higher in dysphonic group compared with nondysphonic group. There were significant associations between the severity of dysphonia, dysphagia, and cough. Dysphonia may be encountered in a quarter of patients with mild-to-moderate COVID-19 and should be considered as a symptom list of the infection. Dysphonic COVID-19 patients are more symptomatic than nondysphonic individuals. Future studies are needed to investigate the relevance of dysphonia in the COVID-19 clinical presentation.
YR 2020
FD 2020-06-04
LK http://hdl.handle.net/10668/22347
UL http://hdl.handle.net/10668/22347
LA en
DS RISalud
RD Apr 17, 2025